Pietschmann P, Kuzmits R, Schernthaner G
II. Medizinische Universitätsklinik, Wien, Austria.
Horm Metab Res. 1990 Feb;22(2):109-13. doi: 10.1055/s-2007-1004861.
In 16 patients with metastatic testicular cancer and 10 age matched male control subjects growth hormone (GH) responses to growth hormone releasing hormone (GHRH; 1 microgram/kg body weight iv.) and thyrotropin releasing hormone (TRH; 200 micrograms iv.) were measured. Basal GH levels and GH levels following stimulation with GHRH or TRH were significantly increased in cancer patients compared to control subjects. 9 patients with testicular cancer were studied both in the stage of metastatic disease and after they had reached a complete remission. In complete remission GH responses to GHRH tended to decrease but the differences did not reach statistical significance. Our data suggest an alteration of hypothalamic and/or pituitary regulation of GH secretion in patients with metastatic testicular cancer.
对16例转移性睾丸癌患者和10例年龄匹配的男性对照受试者，测量了生长激素（GH）对生长激素释放激素（GHRH；1微克/千克体重，静脉注射）和促甲状腺激素释放激素（TRH；200微克，静脉注射）的反应。与对照受试者相比，癌症患者的基础GH水平以及GHRH或TRH刺激后的GH水平显著升高。对9例睾丸癌患者在转移性疾病阶段以及达到完全缓解后均进行了研究。在完全缓解时，GH对GHRH的反应趋于降低，但差异未达到统计学显著性。我们的数据提示转移性睾丸癌患者下丘脑和/或垂体对GH分泌的调节存在改变。
